Literature DB >> 17667801

Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations.

Sang Seop Lee1, Su-Jun Lee, Jungsug Gwak, Hyun-Ju Jung, Houng Thi-Le, Im-Sook Song, Eun-Young Kim, Jae-Gook Shin.   

Abstract

It is well known that CYP2C19 is an enzyme showing genetic polymorphism that may cause marked interindividual and interethnic variation in the metabolism and disposition of its substrates. This study compared the frequency distribution of CYP2C19*1, *2, and *3 alleles in Korean and Vietnamese populations, representing Far Eastern and Southwestern Asian populations, respectively. The presence of the CYP2C19 variant alleles was analyzed in 377 Korean and 165 Vietnamese healthy subjects using a new pyrosequencing method. The respective allele frequencies of CYP2C19*1, *2, and *3 were 64%, 28%, and 8% in Koreans and 69%, 24%, and 5% in Vietnamese. The frequency of poor metabolizer genotype (*2/*2, *2/*3, *3/*3) in Korean (12.5%, 95% confidence interval 11.4-13.6) was not significantly different from that of Vietnamese population (7.2%, 95% confidence interval 6.2-8.2) (P = 0.074). These results obtained from a large number of subjects can be used in comparative studies with other ethnic groups in future clinical research.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17667801     DOI: 10.1097/FTD.0b013e31811f383c

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  7 in total

1.  A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.

Authors:  Su-Jun Lee; Yin Jin Jang; Eun-Young Cha; Ho-Sook Kim; Sang Seop Lee; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

Review 2.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

3.  The frequency of major CYP2C19 genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups.

Authors:  Khalifa Y Alrajeh; Youssef M Roman
Journal:  Per Med       Date:  2022-06-24       Impact factor: 2.119

Review 4.  Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes.

Authors:  Tingyu Wang; Yitian Zhou; Guosheng Cao
Journal:  Eur J Clin Pharmacol       Date:  2021-01-29       Impact factor: 2.953

5.  Development of a multiplex and cost-effective genotype test toward more personalized medicine for the antiplatelet drug clopidogrel.

Authors:  Hye-Eun Jeong; Su-Jun Lee; Eun-Young Cha; Eun-Young Kim; Ho-Sook Kim; Young Hwan Song; Jae-Gook Shin
Journal:  Int J Mol Sci       Date:  2014-05-05       Impact factor: 5.923

6.  Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans.

Authors:  Dong-Jik Shin; Jisun Kwon; Ah-Ram Park; Yousun Bae; Eun-Soon Shin; Sungha Park; Yangsoo Jang
Journal:  Yonsei Med J       Date:  2012-11-01       Impact factor: 2.759

7.  Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine.

Authors:  Su-Jun Lee
Journal:  Front Genet       Date:  2013-02-01       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.